With evidence to support the effect of metformin in Alzheimer’s disease prevention in future clinical trials, we consider metformin as an additional therapy for those who cannot tolerate marketed drugs such as cholinesterase inhibitors, and for high-risk individuals with diabetes, insulin resistance and obesity. The gene discussed is BCHE; the disease is Obesity.